BCYC
Price
$6.94
Change
+$0.08 (+1.17%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
475.44M
44 days until earnings call
PHIO
Price
$2.13
Change
-$0.00 (-0.00%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
12.2M
Interact to see
Advertisement

BCYC vs PHIO

Header iconBCYC vs PHIO Comparison
Open Charts BCYC vs PHIOBanner chart's image
Bicycle Therapeutics
Price$6.94
Change+$0.08 (+1.17%)
Volume$6.56K
Capitalization475.44M
Phio Pharmaceuticals
Price$2.13
Change-$0.00 (-0.00%)
Volume$792
Capitalization12.2M
BCYC vs PHIO Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. PHIO commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and PHIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (BCYC: $6.86 vs. PHIO: $2.13)
Brand notoriety: BCYC and PHIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 90% vs. PHIO: 8%
Market capitalization -- BCYC: $475.44M vs. PHIO: $12.2M
BCYC [@Biotechnology] is valued at $475.44M. PHIO’s [@Biotechnology] market capitalization is $12.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whilePHIO’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • PHIO’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while PHIO’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 4 bearish.
  • PHIO’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than PHIO.

Price Growth

BCYC (@Biotechnology) experienced а -2.00% price change this week, while PHIO (@Biotechnology) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.28%. For the same industry, the average monthly price growth was +6.89%, and the average quarterly price growth was +33.83%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+3.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($475M) has a higher market cap than PHIO($12.2M). PHIO YTD gains are higher at: 18.333 vs. BCYC (-51.000). PHIO has higher annual earnings (EBITDA): -7.45M vs. BCYC (-240.81M). BCYC has more cash in the bank: 721M vs. PHIO (10.8M). PHIO has less debt than BCYC: PHIO (0) vs BCYC (7.2M). BCYC has higher revenues than PHIO: BCYC (19.3M) vs PHIO (0).
BCYCPHIOBCYC / PHIO
Capitalization475M12.2M3,893%
EBITDA-240.81M-7.45M3,235%
Gain YTD-51.00018.333-278%
P/E RatioN/A0.01-
Revenue19.3M0-
Total Cash721M10.8M6,676%
Total Debt7.2M0-
FUNDAMENTALS RATINGS
BCYC vs PHIO: Fundamental Ratings
BCYC
PHIO
OUTLOOK RATING
1..100
1873
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
8850
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
5029

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (19) in the null industry is somewhat better than the same rating for PHIO (54) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than PHIO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as PHIO (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as PHIO (99) in the Biotechnology industry. This means that BCYC’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's Price Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for BCYC (88) in the null industry. This means that PHIO’s stock grew somewhat faster than BCYC’s over the last 12 months.

PHIO's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for BCYC (100) in the null industry. This means that PHIO’s stock grew somewhat faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCPHIO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OSS6.320.76
+13.67%
One Stop Systems
HAFN6.310.24
+3.95%
Hafnia Limited
NTRA172.163.65
+2.17%
Natera
MYGN7.310.07
+0.97%
Myriad Genetics
SNGX2.75-0.17
-5.82%
Soligenix Inc.

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-2.97%
RPTX - BCYC
51%
Loosely correlated
+0.28%
XNCR - BCYC
50%
Loosely correlated
-1.28%
RLAY - BCYC
46%
Loosely correlated
+1.75%
RCUS - BCYC
43%
Loosely correlated
+0.52%
IMCR - BCYC
40%
Loosely correlated
-2.33%
More

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with MTNB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
-2.29%
MTNB - PHIO
50%
Loosely correlated
-4.37%
TPST - PHIO
49%
Loosely correlated
-3.27%
AZTR - PHIO
49%
Loosely correlated
-0.99%
SLRX - PHIO
41%
Loosely correlated
+2.93%
IMNN - PHIO
39%
Loosely correlated
-2.96%
More